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1. Introduction 
According to the American Diabetes Association (http://www.diabetes.org/diabetes-
basics/diabetes-statistics), 2-3 million individuals in the United States have type 1 
diabetes and about 1 in every 400 to 600 children and adolescents was affected by the 
disease in 2007. Similar to other autoimmune diseases, allergies, and asthma, the 
incidence of type 1 diabetes is on the increase at an alarming rate in industrialized 
countries for unknown reasons. The disease is immune-mediated and thought to be 
caused by a combination of genetic and environmental factors that ultimately leads to loss 
of insulin secreting beta cells in pancreatic islets and high levels of blood glucose. High 
sugar levels and autoimmunity cause acute complications, such as ketoacidosis, as well as 
a wide variety of late complications, for example, atherosclerosis, retinopathy, kidney 
failure, neuropathy, and infection. Injection of insulin is a life saving treatment rather than 
a cure, and individuals suffering from type 1 diabetes and receiving insulin still show an 
unacceptable 15 year reduction in life expectancy and complications of the disease 
according to the Juvenile Diabetes Research Foundation (JDRF) 
(http://www.jdrf.org.uk/page.asp?section=163&sectionTitle=FAQs+about+type+1+diabetes). 
The requirement for insulin injection can be alleviated by transplantation of pancreas or 
pancreatic islets, but the procedure is limited by the low number of donors, the out lived 
usefulness of immunosuppression, and the pre-existing autoimmunity which still cause 
~85% of islet transplants to fail 10 years post-transplantation.  
The mammalian immune system is the main line of defense to protect from attacks by 
infection, cancer, and pathological autoimmunity. Leukocytes normally do not destroy host 
tissues or cells because immune cells targeting self-antigens are either deleted in the thymus 
and bone marrow, i.e., central tolerance; or they are under the control of regulatory T cells in 
peripheral tissues, i.e., peripheral tolerance. However, defects in either of these immune 
control systems can result in pathological autoimmunity and large bodies of evidence 
indicate that defects in central as well as peripheral tolerance can contribute to type 1 
diabetes (Geenen et al., 2010). Type 1 diabetes is an organ-specific autoimmune disease 
resulting from the selective destruction of pancreatic insulin secreting beta cells by 
autoreactive CD4 and CD8 effector T lymphocytes which normally play an important role in 
self-protection by killing infected and tumor cells. On the other hand, CD4 and CD8 T 
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lymphocytes also include regulatory cells that control the activity of effector cells, and can 
be drawn upon to ameliorate type 1 diabetes. In the past decade, these regulatory cells, 
especially CD4 T regulatory cells, have become a major immunotherapeutic target for the 
treatment of type 1 diabetes and other autoimmune diseases.  In addition, antigen-
presenting cells like dendritic cells, which present protein-derived antigens to T 
lymphocytes on their major histocompatibility complex molecules, have also received much 
attention not only because they can contribute to disease onset, but also because they can be 
used to induce T regulatory cells (Paul, 1999, Nikolic et al., 2009). 
In addition to direct cell-to-cell interaction, immune cells modulate immune responses by 
secreting small molecular proteins, called cytokines, into their environment. Cytokines 
promote the development and differentiation of immune cells with different functions and 
therefore play an important role in directing immune responses. Several cytokines have 
been used alone and together with other immunotherapeutics for treatment of type 1 
diabetes in animal model systems. One of the largest groups of cytokine is the interleukin 
group, which consists of more than 30 different proteins with interleukin-1, interleukin-2, 
interleukin-4, interleukin-10, and interleukin-15, among others, being potential targets for 
treatment. Other cytokines like tumor necrosis factor-alpha can also be used for type 1 
diabetes treatment. 
Antibodies are another important group of therapeutic molecules that have been 
investigated for type 1 diabetes. Antibodies, or immunoglobulins (Ig), are large Y-shaped 
proteins produced by B lymphocytes found in blood and other bodily fluids of vertebrates 
where their function includes binding to protein antigens and neutralizing pathogens. In the 
case of type 1 diabetes, the therapeutic antibodies that have been developed target self-
antigens synthesized by cells that participate in the inflammatory response and cause the 
disease.  
Under the effect of both genetic and environmental factors, immune cells like CD4 T 
lymphocytes and CD8 cytotoxic T lymphocytes infiltrate pancreatic islets resulting in 
different levels of insulitis (Figure 1). Insulitis ultimately results in the selective destruction 
of pancreatic beta cells as the result of regulatory dysfunction of CD4 T lymphocytes, 
and/or of dendritic cells and other cell types.  
 
 
Fig. 1. Graphic Representation of Mouse Islets with Lymphocyte Infiltration. A. Normal 
islet; B. Islet partially infiltrated by lymphocytes; C. Islet fully infiltrated by lymphocytes. 
Since there is no cure for clinical type 1 diabetes, novel immunotherapeutic approaches 
aimed at preserving and restoring functional endogenous beta cell mass as well as 
protecting transplanted islets are needed to rebuild immune tolerance to beta cells and 
improve the condition of type 1 diabetic patients.  One of the animal models closest to 
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human type 1 diabetes and most often used for studying the disease is the non-obese 
diabetic (NOD) female mouse, which is a spontaneous diabetes model that has helped to 
dissect the various stages of disease progression in human (Zhang et al., 2008, Ridgway, 
2003). A variety of immunotherapies are being investigated in non-obese diabetic mice to 
treat type 1 diabetes. They can be divided into four main categories: first, non-antigen-
specific therapies such as antibody therapies targeting effector cells; second, antigen-specific 
therapies such as protein and DNA vaccines targeting diabetic autoantigens; third, other 
immunotherapies such as bacille Calmette-Guérin (BCG), vitamin D3, and fourth, 
combinational therapies which combine antigen specific and non-specific therapies (Figure 
2). Bench-to-bedside translation of these different approaches has already identified a 
number of promising therapies, which will be the main focus of this chapter. The strong 
impetus to develop prophylactic and therapeutic approaches for the disease is reflected by 
the activity of organizations like TrialNet (http://www.diabetestrialnet.org/) and the 
Immune Tolerance Network (http://www.immunetolerance.org/). TrialNet is an expansion 
of the Diabetes Prevention Trial (DPT-1) network, but with an emphasis not only on 
diabetes prevention but also on trials to prevent further destruction of islet beta cells in 
patients with type 1 diabetes. 
2. Antibody therapies 
Intervention studies using antibodies for type 1 diabetes in the 1980s demonstrated a 
potential for preserving insulin C-peptide level which serves as an indication of insulin 
secretion by beta cells. However, they were eventually abandoned due to the adverse side 
effect profiles of the agents being used (You et al., 2008). Pilot studies of new 
immunosuppressive and immunomodulatory agents with decreased side-effect profiles 
have recently shown promise in preserving C-peptide in new-onset type 1 diabetic patients. 
Some of these agents are specifically designed monoclonal antibodies targeting immune 
effector cells, e.g., anti-CD3, anti-CD20, anti-CD25 (daclizumab), and anti-thymocyte 
globulin are being tested in clinical trials for type 1 diabetes. Other antibodies, such as anti-
CD154 (MR1) have been tested in the female non-obese diabetic mouse. 
The first anti-CD3 antibody used clinically was a murine monoclonal IgG2 antibody, OKT3, 
which was identified while antibodies were investigated as lymphocytic mitogens 
(Kaufman & Herold, 2009). CD3 is a protein complex found on the cell surface of T cells and 
is involved in transduction of signals originating from the antigen receptor to start a cascade 
of events initiating activation of the T cell. The binding between anti-CD3 antibody and CD3 
on T cells can inhibit lysis of targets by T cells. Along with potent mitogenic activity, OKT3 
was found to be a potent inducer of cytokines, specifically, tumor necrosis factor-alpha, 
interleukin-2, and interferon-gamma. Among these induced cytokines, interleukin-2 is 
necessary for T regulatory cell proliferation and tumor necrosis factor-alpha and interferon-
gamma are considered as regulatory cytokines. These characteristics made anti-CD3 a 
potential therapeutic agent for both transplantation medicine and anti-tumor activity in the 
clinic. Unfortunately, the toxic side effects of OKT3 became clear after patients receiving the 
drug immediately developed chills, fever, hypotension, and in some cases, dyspnea. The 
toxicity was thought to be associated with a cytokine, specifically tumor necrosis factor-
alpha from T cells in response to the drug. This effect was attributed to the anti-CD3 
mediated cross-linking of T cells, i.e., the anti-CD3 antibody causing linkage of T cells 
bearing CD3 molecules and cells bearing the Fc (fragmental crystallizable region of the 
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antibody molecule) receptor. This cross-linking is thought to activate both the T cell and the 
Fc receptor-bearing cells, leading to the massive release of cytokines. These toxic side effects 
severely limited the clinical application of anti-CD3 to type 1 diabetes. 
 
 
Fig. 2. Immunotherapies for Type 1 Diabetes. Without immunotherapy (top), pro-diabetic 
islets ultimately become diabetic islets after destruction of insulin-secreting beta-cells. 
Immunotherapies for type 1 diabetes can protect pro-diabetic islets from further destruction 
and permit them to regain function. A variety of immunotherapies, either alone or in 
combination, has been shown to stop pathological autoimmunity and protect islets to 
ameliorate type 1 diabetes. 
To circumvent these problems, new antibodies were engineered to reduced Fc receptor 
binding after amino acid substitutions in the Fc portions of the antibody (Kaufman & 
Herold, 2009). Although reduced Fc receptor binding was predicted to eliminate T cell 
activation and cytokine release, the new anti-CD3 antibodies are still mildly mitogenic, i.e., 
T cell proliferation can be shown in vitro and even mild cytokine release has been observed. 
Nevertheless, it is important to note that the new anti-CD3 monoclonal antibodies differ 
greatly from OKT3 in their induction of T cell activation in vivo, and that the toxic side 
effects have been significantly reduced. In addition, the anti-CD3 antibodies derived from 
mouse generally are fully humanized to minimize the potential immunogenicity associated 
with heterogenic antibody isotype between mouse and human. 
The modified anti-CD3 antibodies have been shown to be as effective as the full-length 
molecule but with reduced morbidity (Chatenoud et al., 1994). Using this treatment, 64–80% 
of treated diabetic non-obese diabetic mice returned to a euglycemic state without 
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glycosuria while none of the non-obese diabetic mice treated with control immunoglobin 
recovered. In addition, the new antibodies could also protect transplanted allogeneic 
pancreatic islets in diabetic non-obese diabetic mice (Chatenoud et al., 1997). The mice could 
still reject allogeneic skingrafts and remain resistant to adoptive transfer of diabetogenic T 
cells, suggesting that their immune system was intact and that only beta cell specific 
immune responses were affected. However, results indicated that treatment of 4- and 8-
week old mice did not prevent diabetes, but did protect 12-week-old mice, which indicated 
that the anti-CD3 was only effective when used after the onset of the disease. 
Humanized non-Fc receptor binding anti-CD3 monoclonal antibodies include otelixizumab, 
teplizumab, and visilizumab. Teplizumab was shown to preserve C-peptide production up to 
five years after a single course of twelve days of treatment of new-onset type 1 diabetic 
patients in phase I/II clinical trials (Herold et al., 2009). Insulin is synthesized in the pancreas 
firstly as pro-insulin consisting of the A, C, and B peptide moieties. Mature active insulin is 
obtained after excision of the C peptide and folding/assembly of the A chain and B chain. 
Thus levels of C-peptide can be used as an indication of insulin secretion activity by -cells. 
There may be several therapeutic mechanisms involved: induction of regulatory T cells, 
increased proportion of CD8+ T cells, increased expression of Foxp3 in CD8+ T cells, as well as 
induction of apoptotic cells.  Similarly, otelixizumab could preserve residual beta-cell function 
for at least 18 months in patients with recent onset type 1 diabetes who were under treatment 
for six consecutive days (Keymeulen et al., 2005). However, anti-CD3 based approaches have 
suffered a setback because of the announced suspension of Phase III clinical trials for type 1 
diabetes by MacroGenics and Eli Lilly as well as by Tolerx and GlaxoSmithKline due to lack of 
efficacy (GEN news, 2010; GSK Press Release, 2011).  Previously, ulcerative colitis Phase II/III 
trials of visilizumab (trade name Nuvion) by PDL BioPharma Inc. had also been stopped due 
to inefficacy and poor safety profile (Lawler, 2009), which constitutes another setback.   
Anti-CD25 IgG1 antibody (daclizumab) is another humanized recombinant monoclonal 
antibody which targets T cells. It is approximately 10% murine and 90% human, and 
activates T regulatory cells in vivo since the antibody inhibit initial T cell proliferation and 
differentiation but not initial activation (Egan et al., 2001). When used with the 
immunosuppressants rapamycin and tacrolimus, daclizumab maintains normal islet 
function in human recipients of transplanted allogeneic islet grafts. This glucocorticoid-free 
regimen appears to be highly beneficial for islet survival and function, as all patients were 
insulin independent (Shapiro et al., 2000). Daclizumab has also been used with success in 
human pancreas transplantation (Sutherland et al., 2001). 
Monoclonal antibodies against CD154, also known as CD40 ligand, have also been used for 
treatment of type 1 diabetes. The CD154 protein is primarily synthesized by activated CD4 T 
cells, and binds to the CD40 receptor on antigen-presenting cells. CD40 receptor 
engagement induces activation through co-stimulation in antigen-presenting cells like 
dendritic cells, macrophages and B cells. Anti-CD154 monoclonal antibodies will bind to 
CD154 on the surface of CD4 T lymphocytes, and block stimulation of antigen-presenting 
cells (Howard & Miller, 2004). The application of anti-CD154 antibodies was shown to 
prevent expansion of CD40 expressing T cells, later called T helper 40 cells, which are highly 
pathogenic in the non-obese diabetic mouse model and human diabetes (Waid, et al., 2004). 
In addition, anti-CD154 monoclonal antibodies induced islet allograft tolerance involving a 
dominant mechanism associated with intragraft regulatory cells, and prevented 
autoimmune diabetes in non-obese diabetic mice, possibly because it inhibits effector T cells 
by expending regulatory T cell (Rigby et al., 2008).  
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Anti-thymocyte globulin (ATG) consists of antibodies from horse and rabbit against human 
T-lymphocytes. Its administration as intraperitoneal injections of 500 micrograms antibodies 
stops new-onset diabetes and induces long-term tolerance in non-obese diabetic mice 
(Simon et al., 2008).  Treatment was associated with increased frequency and activity of 
CD4+CD25+ T regulatory cells, as well as altered alteration of dendritic cell profile and 
function (Bresson and von Herrath, 2011).  However, the treatment was efficacious only 
when administered late in the prediabetic phase (12-week of age) or after recent-onset. 
Another report showed that the antibodies failed to protect diabetes in a more stringent 
virus (RIP-LCMV) induced diabetes model due at least partially to the inability to maintain 
or increase a sufficient CD4+CD25+ T regulatory cell frequency.  
Human clinical trials of anti-thymocyte globulin suggest that short term therapy (9 mg/kg 
followed by 3 consecutive doses of 3 mg/kg/day intravenously) in eleven recent onset 
patients, i.e., within 4 weeks of diagnosis and with residual post-glucagon C-peptide levels 
still over 0.3 nmol/l, contributed to the preservation of residual C-peptide production and 
to lower insulin requirements in the first year following diagnosis (Saudek et al, 2004). 
Nevertheless, significant adverse effects consisting mainly of transient fever and moderate 
symptoms of serum sickness were observed during the first month of treatments. Two other 
clinical trials are ongoing, which include a phase II trial to determine whether 
thymoglobulin treatment can halt the progression of newly diagnosed type 1 diabetes when 
given within 12-weeks of disease diagnosis (Gitelman. 2007); and a phase I/II trial to 
determine if giving a combination therapy consisting of Thymoglobulin (anti-thymocyte 
globulin) and Neulasta (granulocyte colony-stimulating factor, GCSF) given to established 
type 1 diabetes patients is safe and preserves insulin production (Haller, 2010). 
Although type 1 diabetes is considered a T cell-mediated disease, recent data have indicated 
a role for antigen presentation by B lymphocytes in disease pathogenesis. In fact, anti-CD20 
monoclonal antibody treatment of 5-week-old non-obese diabetic female mice reduces B cell 
numbers by approximately 95%, decreases insulitis, and prevents diabetes in >60% of mice 
(Xiu et al., 2008). Furthermore, anti-CD20 monoclonal antibody treatment of 15-week old 
female non-obese diabetic mice significantly delays diabetes onset. A recent clinical trial 
delivering a four-dose course of anti-CD20 antibody (rituximab) 3 months after diagnosis of 
diabetes onset showed a significant improvement in beta cell function in 23% of patients at 1 
year (Pescovitz et al., 2009).  No beneficial effects were noted in placebo-treated subjects. 
These patients also showed significant improvements in clinical parameters like hemoglobin 
A1c level, which is a indicator of average blood glucose level, and decreased insulin use. 
After 3 months, however, there was a parallel decline in beta cell function in the drug and 
placebo treated subjects. 
Clearly, antibody therapies can be effective in controlling diabetes. However, they cannot 
always be combined with other therapies in the clinic. For example, clinical trials of the 
combined application of daclizumab (anti-CD25) with either intensive insulin therapy or 
mycophenolate mofetil reported failure in preserving beta-cell function in clinic (Rother et 
al., 2009b; Gottlieb et al., 2010), and the anti-diabetic effects of anti-CD3 are negated by 
rapamycin in non-obese diabetic mice (Valle et al., 2009).  In addition, antibodies act 
systemically in a non-specific manner and can interfere with normal immune function. For 
example, anti-CD20 and anti-CD3 monoclonal antibodies have caused treatment-related 
adverse events in some patients during clinical trials (Pescovitz et al., 2009; Keymeulen et 
al., 2005; Herold et al., 2005). The recent announcement by Biogen and Roche that clinical 
trials of an anti-CD20 monoclonal antibody for rheumatoid arthritis and systemic lupus had 
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to be stopped due to death from opportunistic infection illustrates further the potential risks 
of certain monoclonal antibody treatments for autoimmune diseases.  
3. Cellular and cytokine therapies 
The main sign of pathosis in diabetic pancreatic islets is leukocyte infiltration or insulitis 
(Figure 1). Studies of islet-infiltrating cells have yielded clues to new therapeutic approaches 
by identifying immune cells and their associated molecules, such as cytokines, to suppress 
the disease. Preclinical and clinical trials of cellular therapies and cytokine therapies are 
currently ongoing, and will be discussed in this section. 
3.1 Cellular therapies 
Type 1 diabetes-associated deficiencies have been observed in several immune cell 
populations, such as CD4 T cells, CD8 T cells, B cells, dendritic cells, macrophages and NK 
cells in both non-obese diabetic mice and humans (Sgouroudis & Piccirillo, 2009; Luczyński 
et al., 2009). Regardless of whether diabetes is the result of increased effector cell activity or 
decreased regulatory cell function, the goal of cellular and many other therapies is to 
increase the regulatory function of cells like T regulatory lymphocytes and dendritic cells. 
Both cell types are important not only for therapeutic purposes, but are also suspected to 
play a determining role in the development of diabetes. T regulatory cellular therapies are 
currently at the preclinical stage and human T regulatory cell expansion strategies 
performed in vitro are under development.  
T regulatory cells play a vital role as suppressive cells that regulate and control the effector 
arm of the immune system. In the past decade, an overwhelming body of literature has 
confirmed that CD4+CD25+FoxP3+ and other T regulatory cells comprise a dominant 
mechanism regulating autoimmunity as well as responding to infection and cancer. These 
findings are further confirmation that T regulatory cell dysregulation is implicated in 
autoimmune disorders like type 1 diabetes. In the non-obese diabetic model system, the 
defects of T regulatory cells result in the loss of control of autoaggressive T cells and 
diabetes progression (Tang & Bluestone, 2006). In humans, defects in polyclonal regulatory 
T cell have also been proposed as a mechanism by which individuals develop type 1 
diabetes (Kukreja et al., 2002).  Here T regulatory cell numbers decrease in child (age 9.4 ± 
2.16 years) and adult (age 45.2 ± 9.7 years) patients. Another report showed that while the T 
regulatory cell numbers remain normal, they are associated with functional deficiency in 
adult patients (age 32.3 ± 6.8 years) (Lindley et al., 2005). Therefore, control of pathological 
autoimmunity through the induction of functional T regulatory cells is a highly promising 
approach. 
Surprisingly, central tolerance mechanisms associated with regulatory cells are generally 
intact in non-obese diabetic mice (Feuerer et al., 2007), and the frequency and function of 
single positive CD4+Foxp3+ T regulatory cells in the thymus of these animals is comparable 
to that of diabetes-resistant C57/BL6 mice (Tritt et al., 2008). The results suggest that a 
defect in the regulatory T cell population most likely happens in the peripheral immune 
system after a certain age. T regulatory cells are diverse in their phenotype and mechanisms 
of function, and as such investigators are developing various types of induced T cell 
precursors (e.g. antigen targeting specificities) with a variable degree of regulatory potential. 
It is possible to induce and expand islet antigen-specific T regulatory cells in vitro from both 
non-obese diabetic mice and humans. T regulatory cells from non-obese diabetic mice could 
www.intechopen.com
 
Type 1 Diabetes – Pathogenesis, Genetics and Immunotherapy 
 
362 
be efficiently expanded in vitro using interleukin-2 and beads coated with a recombinant 
islet peptide mimic, a MHC class II molecule, and anti-CD28 monoclonal antibody. The 
expanded cells expressed normal surface markers like CD4, CD25, Foxp3, CD62L, GITR, and 
CTLA-4 in mice; and CD4, CD127lo, CD25, and FOXP3 in humans. Once activated by the 
islet specific antigen, the T regulatory cells could suppress T effectors with other specificities 
both in vitro and in vivo. This feature is important for controlling type 1 diabetes in which 
numerous self-antigens are targeted by pathogenic effector cells. Importantly, the islet 
antigen specific T regulatory cells were more efficient than non-specific polyclonal T 
regulatory cells in suppressing autoimmune diabetes (Masteller et al., 2005; Putnam et al., 
2009). 
Results from T regulatory cell analysis of type 1 diabetic patients are varied, with either 
decreased cell frequency, unaltered T regulatory cell frequency with marked decrease in 
suppressive activity in vitro, or no difference compared to healthy controls (Kukreja et al., 
2002; Lindley et al., 2005; Putnam et al., 2005). These variable results could be caused by 
different factors including different methods of T regulatory cell isolation and purification, 
the lack of functional tests for islet specific T regulatory cells in the blood, or simply 
different disease etiologies. Furthermore, studies in murine models indicate that T 
regulatory cells exert their function within the target organ undergoing autoimmune attack 
rather than solely in the lymph node draining sites. Thus, subtle functional differences in the 
T regulatory cell pool within sites of inflammation may not be adequately reflected in the 
peripheral blood and lymph node compartments, which are the main source of samples for 
human clinical data (Sgouroudis et al., 2009). A remaining question is whether changes in T 
regulatory cell function are the cause of diabetes onset or the uncontrolled activation and 
expansion of diabetogenic T effector cells are the cause of diabetes onset. 
Similar to cells in mice, human T regulatory cells can be expanded in vitro. T regulatory cells 
from recent onset type 1 diabetic patients were expanded using anti-CD3 and anti-CD28 
coated microbeads and interleukin-2 cytokine. Importantly, suppressive function, lineage 
markers such as FOXP3, and cytokine productions were similar to the T regulatory cells 
from healthy control subjects (Putnam et al., 2009). A phase I clinical trial of CD4+CD127lo/-
CD25+ polyclonal T regulatory cells expanded using anti-CD3/anti-CD28 beads plus 
interleukin-2 started in 2010. The primary purpose of the trial is to assess the safety and 
feasibility of intravenous infusion of ex vivo selected and expanded autologous polyclonal 
regulatory cells in patients with type 1 diabetes to support dose selection for a future 
efficacy trial. The study also aims to assess the effect of T regulatory cells on beta cell 
function as well as on other measures of diabetes severity and the autoimmune response 
underlying type 1 diabetes (Gitelman & Bluestone, 2010).  
In addition to T regulatory cells, dendritic cells can be cultured in vitro for in vivo 
applications. Dendritic cells are known as the most potent antigen-presenting cells and play 
a vital role in the control of immune homeostasis. Dendritic cells initiate T cell-mediated 
immunity and maintain immune tolerance in the periphery through activation of T 
regulatory cells and other mechanisms. Dendritic cells are the only professional antigen-
presenting cells, as their main function is to prime naive T cells. They are the exclusive 
antigen-presenting cell subset capable of potentiating T regulatory cell proliferative and 
suppressive functions both in vitro and in vivo. As such, dendritic cells are at the crossroad of 
pathogenesis and therapy of autoimmune diseases like type 1 diabetes. Together with T 
regulatory cells, dendritic cells have been a main target for both in vitro and in vivo 
approaches to treat type 1 diabetes. The exact mechanism of tolerance induction by dendritic 
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cells in diabetes remains to be established, but it likely includes inhibition and killing of 
effector T cells and induction of regulatory T cells (Feili-Hariri et al., 2006; Nikolic et al., 
2009). 
A dendritic cell clinical phase I safety trial is currently being conducted with type 1 diabetic 
patients (Phillips et al., 2009). The proposed studies describe a randomized trial to evaluate 
the safety of a new diabetes-suppressive cell vaccine, consisting of autologous monocyte-
derived dendritic cells treated ex vivo with antisense phosphorothioate modified 
oligonucleotides targeting the primary transcripts of the dendritic cell co-stimulatory 
molecules CD40, CD80, and CD86 (immunoregulatory dendritic cells; iDC). Fifteen patients 
exhibiting fully-established, insulin-dependent type 1 diabetics, without any diabetes-
related complications, infectious disease, or other medical anomaly, have been enrolled to 
establish safety of the approach. 7/15 patients have been administered autologous control 
dendritic cells and 8/15 patents have been administered immunoregulatory dendritic cells. 
The study is anticipated to be complete within a twelve month period. 
Solely expanding cell population in vitro may not be sufficient as a therapy for an organ 
specific autoimmune disease, since it will be a systemic treatment and may be inducing 
significant off-target effects, such as general immuno-suppression that will compromise 
beneficial immune responses to infections and cancers. In addition, current methodologies 
are limited in terms of the capacity to isolate and expand a sufficient quantity of 
endogenous antigen specific human cells for therapeutic intervention at low cost. Even a T 
regulatory cell induced with antigen specificity possesses bystander suppressive function 
(Brusko et al., 2010; Masteller et al., 2005), and the induced antigen specific T regulatory cells 
could quickly revert to Foxp3 negative CD4 T cells in a Foxp3 transgenic mouse model 
(Koenecke et al., 2009). Therefore, significant improvements may have to be made before 
cellular therapies can be safely applied to humans. 
3.2 Cytokine therapies 
Several immunotherapies for type 1 diabetes have used cytokines and other molecules such 
as fusion proteins targeting the costimulatory pathway (http://en.wikipedia.org/wiki/Co-
stimulation). For example, cytokines like interleukin-2 provides vital survival signals to 
regulatory cells and can trigger the death of effector T cells, and impede interleukin-15 
driven expansion of memory cells. In addition, interleukin-4, tumor necrosis factor-alpha, 
interferon-alpha, and lymphotoxin cytokines can exert selective effects upon crucial 
lymphocyte subset populations in vivo that may also enable translation into potent 
therapies. Preclinical trials and a few clinical trials of cytokine therapies will be addressed in 
this section. 
Pro-inflammatory cytokines may impair islet viability and function by activating 
inflammatory pathways. Interleukin-1 beta is a master inflammatory cytokine that is 
synthesized early during inflammation by a wide variety of cells. Interleukin-1 receptor-
deficient non-obese diabetic mice have a reduced development incidence of diabetes 
(Thomas et al., 2004). Anakinra, which is a clinically approved recombinant human 
interleukin-1 receptor antagonist, can block the effects of interleukin-1 beta on rat islet 
cultured in vitro, and inhibits the activation of interleukin-1 beta dependent inflammatory 
pathways to protect islets from apoptotic impairment (Schwarznau et al., 2009). In addition, 
short term treatment with anakinra resulted in reduced ability of mononuclear cells to traffic 
to sites of inflammation in a small group of patients with type 1 diabetes. This suggests that 
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mechanistic studies from large scale trials using interleukin-1 blockade in type 1 diabetes 
should focus on changes in monocyte trafficking and the interleukin-8 pathway (Sanda et 
al., 2010). Moreover, an adenoviral vector encoding interleukin-1 beta receptor antagonist 
together with another anti-inflammatory factor, i.e., hepatocyte growth factor, can reduce 
apoptosis of transplanted islets, and improve their survival in streptozotocin induced 
diabetes leading to lower blood glucose levels, as well as increased serum insulin and C-
peptide levels (Panakanti & Mahato, 2009). Nevertheless, initial clinical data do not suggest 
that interleukin-1 blockade alone can prevent or reverse type 1 diabetes (Donath & 
Mandrup-Poulsen, 2008). 
Interleukin-2 is another significant cytokine which has an important role in promoting T 
regulatory cell survival. Defective interleukin-2 or interleukin-2 receptor signaling in CD4 T-
cells of type 1 diabetic subjects contributes to decreased persistence of FOXP3 expression 
that may impact establishment of tolerance (d'Hennezel et al., 2010).  Therefore, interleukin-
2 could be used as a therapeutic target for the restoration of Foxp3+ regulatory T cell 
function in organ specific autoimmunity. Indeed, administration of a low dose of 
interleukin-2 in prediabetic non-obese diabetic mice results in restoration of CD25 
expression, survival of intra islet T regulatory cells and prevention of type 1 diabetes, which 
are associated with enhanced synthesis of T regulatory cell associated proteins and 
suppression of interferon-gamma (Grinberg-Bleyer et al, 2010). Moreover, a cytolytic 
interleukin-2 and Fc fusion protein binding specifically to the interleukin-2 receptor is 
capable of suppressing induced diabetes in non-obese diabetic mice (Zheng et al., 1999). Co-
administration of interleukin-2 and rapamycin to 10-week old non-obese diabetic mice 
synergistically prevents diabetes development for 13 weeks post therapy. Furthermore, the 
treatment could also synergistically protect transplanted syngeneic islet in diabetic non-
obese diabetic mice most likely due to the decreasing numbers of leukocytes, which were 
associated with increasing apoptosis of these cells, and a shift from T helper-1 (pathogenic) 
to T helper-2 and T helper-3 (protective) lymphocytes (Rabinovitch et al., 2002). 
It has been hypothesized that manipulating the levels of interleukin-2 or interleukin-15 
available to activated effector and regulatory T cells may provide a means to govern the 
balance of cytopathic T cells and regulatory T cells in vivo.  Interleukin-15 is a cytokine that 
can induce massive apoptosis of recently activated pathogenic cells but not regulatory T 
cells. The combined therapy of interleukin-2 and immunoglobin fusion protein, mutated 
interleukin-15 and immunoglobin fusion protein plus rapamycin restores euglycemic state 
in recent-onset diabetes, and prolongs transplanted syngeneic islet survival in diabetic non-
obese diabetic mice. It also decreases inflammatory gene expression in pancreatic draining 
lymph nodes and other tissues (Koulmanda et al., 2007). Based on the results of these 
preclinical studies, the Immune Tolerance Network is conducting a trial of interleukin-2 and 
rapamycin in a Phase I clinical trial with new onset type 1 diabetic human patients starting 
2007 (http://clinicaltrials.gov/ct2/show/NCT00525889). 
In addition to interleukin-1, both tumor necrosis factor-alpha and interferon-gamma have a 
direct cytotoxic effect on beta cells, and are postulated to be a direct cause of pancreatic islet 
beta cell destruction. Nevertheless, tumor necrosis factor-alpha has a more complex role in 
diabetes progression, and sometime appears more like a regulating instead of a pathological 
molecule. Tumor necrosis factor-alpha may prevent development of insulitis and diabetes, 
and even the adoptive transfer of diabetes by lymphocytes into young non-obese diabetic 
mice (Jacob et al., 1990). Moreover, neutralization of tumor necrosis factor-alpha accelerated 
diabetes in older mice, but prevented disease at a younger age. Tumor necrosis factor-alpha 
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or its agonists selectively kill autoreactive CD8, but not CD4 T cells derived from the blood 
of human type 1 diabetic patients (Ben et al, 2008). Most recently, a report from a small pilot 
trial (Phase I/II) of newly diagnosed pediatric patients found that administration of the 
soluble tumor necrotic factor receptor, etanercept, resulted in lower hemoglobin A1c level, 
and increased endogenous insulin production, suggesting preservation of beta-cell function 
in diabetic patients (Mastrandrea et al., 2009). 
Interferon-alpha administered orally to non-obese diabetic mice caused decreased insulitis, 
increased mitogen-induced production of interleukin-4, interleukin-10 (T helper-2 like 
cytokines), and interferon-gamma secretion in splenocytes. The administered dose was 10 
units daily from 9-week old, and suppressed diabetes from 100% diabetic mice in controls 
down to 10% in 24-week old mice. In addition, adoptive transfer of thirty million 
splenocytes intraperitoneally into 8-week old non-obese diabetic mice suppressed diabetes 
(Brod et al., 1998). In Phase I clinical trials of interferon-alpha, 10 newly diagnosed type 1 
diabetic patients (ages 10-25, daily or every other day for 1 year) received an oral dose of 
30,000 units of the cytokine within 1 month of diagnosis. The treatment induced at least a 
30% increase in stimulated C-peptide levels at 0, 3, 6, 9, and 12 months compared to baseline 
(Brod et al., 2001). A phase I/II trial of safety and efficacy treated 31 new-onset patients 
(ages 3-25, daily for 1 year), and found that patients in the 5,000 units treatment group 
maintained increased beta-cell function 1 year after study enrollment compared with 
individuals in the placebo group (Rother et al., 2009a). In contrast, the effect was not 
observed in the 30,000 units treatment group.  
Other cytokines, such as interleukin-4 and interleukin-10, have been reported to suppress 
type 1 diabetes at varying levels in animal models when delivered as part of a plasmid or 
virus vector (Wolfe et al., 2002; Goudy et al., 2001). Nonetheless, similar to antibodies, 
cytokine approaches are also systemic and associated with undesirable side-effects because 
of non-specificity in vivo. 
4. Protein vaccine immunotherapies 
It is now well established that loss of tolerance to beta-cell self-antigens, i.e., autoantigens, 
plays a determining role in the pathogenesis of type 1 diabetes. Autoantigens are self-
molecules that become the target of the immune system under non-homeostatic conditions, 
which result from the combinations of genetic abnormalities with unknown environmental 
factors that ultimately lead to loss of immune tolerance for self-antigens. The autoantigens 
associated with type 1 diabetes covered in this chapter are heat shock protein 60, insulin, 
and glutamic acid decarboxylase 65, because they are therapeutic targets in ongoing clinical 
trials for type 1 diabetes. Nevertheless, there are others autoantigens like tyrosine 
phosphatase IA2, which is a target of humoral response in humans similar to insulin and 
glutamic acid decarboxylase 65, as well as the islet-specification efflux transporter znT8 and 
chromogranin A (Wenzlau et al., 2007; Stadinski et al., 2010), which will not be covered in 
this chapter. 
The goal of autoantigen delivery as an immunotherapy is to re-establish at least some 
degree of immune tolerance activity for a target tissue to suppress pathological 
inflammation and ameliorate disease (Ludvigsson, 2009). This is not a new concept as it was 
used early in the 20th century to treat allergies to normally harmless foreign antigens 
(Krishna & Huissoon, 2011). In recent years, immunoregulatory vaccination, also sometimes 
referred to as “negative” or “inverse” vaccination, has become increasingly attractive as an 
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immunotherapy principally because of the revival of the suppressor T cell concept, now 
named T regulatory cells. We know that T regulatory cells like CD4+CD25+Foxp3+ cells that 
are natural, i.e., thymus derived, or adaptive, i.e., induced in the periphery, are fundamental 
for immune tolerance because deleterious mutations in the Foxp3 gene causes systemic 
autoimmunity in both mice and humans (Mercer & Unutmaz, 2009). Accordingly, it is 
anticipated that approaches that modulate T regulatory cells activity will provide the means 
to mimic the immune system and finally control inflammation in a tissue specific manner. 
Two particularly apparent properties of T regulatory cells raise the hopes that development 
of T regulatory cells inducing immunoregulatory vaccines could lead to potent means of 
controlling inflammation (Tang & Bluestone, 2008). The first property is by-stander 
suppression, which is the capacity of T regulatory cells induced by a specific antigen to 
directly suppress effector cells induced by other antigens at the site of inflammation. The 
second property is infectious tolerance, which is the ability of a T regulatory cell clone to 
induce T regulatory cells of different antigen specificities. Therefore, T regulatory cells are 
naturally equipped to amplify in a targeted manner an immunoregulatory response induced 
by an immunoregulatory vaccine. 
The first immunoregulatory vaccine to be successfully translated to the clinic was a peptide 
vaccine. Peptide vaccines are short polymers of amino acids derived from full-length proteins 
characterized as autoantigens. They are chosen based on their ability to bind as epitopes to 
major histocompatibility complex molecules on antigen-presenting cells. The bound peptide is 
then presented to the receptor of a restricted number of T lymphocytes, preferably T 
regulatory cells in the case of type 1 diabetes. The advantage of a peptide vaccine compared to 
the full-length parent protein is that it can focus the desired immune response by activating 
only a small number of T cell clones instead of multiple clones that may not be all relevant. The 
disadvantage of a peptide vaccine is that its activity will vary depending on the MHC 
molecules synthesized by a given individual. In this case, polypeptide vaccines are more 
advantageous because they ensure that all treated patients will present an epitope. Both 
peptide and polypeptide vaccines have been used with varying outcomes in type 1 diabetes. 
4.1 Heat-shock protein 60 peptide vaccine (Diapep277) 
Diapep277 was the first peptide vaccine successfully used in clinical trials for type 1 
diabetes. Irun Cohen and colleagues identified peptide p277 derived from heat shock 
protein 60 and found that subcutaneous injection of 100 micrograms of the peptide in 
incomplete Freund’s adjuvant inhibited the development of spontaneous diabetes in non-
obese diabetic mice (Elias & Cohen, 1995). The main function of eukaryotic heat shock 
protein 60 is as a mitochondrial chaperone that assists in protein folding and translocation in 
the mitochondrial matrix (Fischer et al., 2010). From an immunological standpoint, 
mammalian heat shock proteins like HSP60 can also act as damage associated molecular 
patterns that are released or presented by dying cells and can activate antigen-presenting 
cells of the innate immune system (Chen et al., 1999). Heat shock proteins activate 
macrophages and dendritic cells through Toll-like receptor 4, which belongs to a class of 
membrane-bound proteins that act as sensors for immune cell activation, and promote 
proinflammatory effector immune responses. Paradoxically, heat shock proteins can also 
have T cell mediated anti-inflammatory effects through Toll-like receptor 2, and DiaPep277 
peptide functions through a Toll-like receptor 2-mediated mechanism (Eldor et al., 2009). 
Heat shock protein 60 has been found to be a possible autoantigen in type 1 diabetic 
children and murine models. It is found located on the membranes of the beta cell insulin 
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secretary granules in pancreatic islets, and shares significant homology to bacterial heat 
shock protein 65.  Epitope scanning of heat shock protein 60 with antibodies identified the 
peptide Diapep277 with the amino sequence VLGGGVALLRVIPALDSLTPANED as an 
immunodominant epitope in type 1 diabetic children (Brudzynski et al., 1992; Horváth et al., 
2002).  
As mentioned previously, in contrast with full-length heat shock protein 60, DiaPep277 has no 
effect on Toll-like receptor 4 and activates anti-inflammatory effectors through Toll-like 
receptor 2. Toll-like receptor 2 promotes cell adhesion, inhibits migration, and modulates 
cytokine secretion resulting in a deviation to a T helper-2 cytokine profile that is associated 
with a shift from an inflammatory to a regulatory response. Indeed, the peptide inhibits 
diabetes by shifting T cell responses from a T helper-1 to a T helper-2 like activity as indicated 
by the presence of pep277-specific antibodies of the IgG1, but not of the IgG2a isotype, and 
production of interleukin-4 and interleukin-10 in spleens of non-obese diabetic mice (Elias et 
al., 1997). The peptide also causes a decrease in the number of interferon-gamma producing 
islet T cells, which is concomitant with increased islet numbers and the arrest of type 1 
diabetes when administered to 12-week old non-obese diabetic mice (Ablamunits et al., 1998). 
Moreover, the peptide induces islet protective T cells that can be adoptively transferred to 
protect non-obese diabetic-SCID mice from diabetes (Ablamunits et al., 1999).  
Clinical trials of the peptide vaccine DiaPep277 have been ongoing and results have been 
reported since 2001. Patients were treated with 0.2, 1, and 2.5 mg doses of the peptide 
(Pfleger et al., 2010). The results showed that increased T helper-1 related cytokine responses 
(interferon-gamma) were associated with lower beta cell function whereas T helper-2 
(interleukin-5, interleukin-13) and T regulatory activity (interleukin-10) related cytokine 
responses were positively associated with beta-cell function in adults and children. 
DiaPep277 also acts as an inhibitor of human T cells response. The signal transduction 
cascade induced by the p277 peptide involves suppression of both cytokine signaling 3 
(SOCS3) expression and signal transducer and activator of transcription 3 (STAT3) (Zanin-
Zhorov et al., 2005). This inhibition of T cell mediated inflammation by the peptide is due to 
down-regulation of T cell chemotaxis and reduced secretion of proinflammatory cytokines. 
A randomized, double blind, phase Ib/II study of DiaPep277 tested its safety and efficacy, 
which was undertaken with recent onset type 1 diabetes patients with remaining insulin 
production (Huurman et al., 2007). Forty-eight adult patients were administered 
subcutaneous injections of 0.2, 1.0 or 2.5 mg DiaPep277 (12 patients per dosage) at entry, 1, 
6, and 12 months, or they received four placebo injections (12 patients). C-peptide levels 
decreased in all groups with the exception of patients receiving the 2.5 mg dose, and 
decreased C-peptide production was attenuated in treated patients versus placebo. The 
main conclusion was that the treatment was safe, and may have a beneficial effect on C-
peptide levels over time, although this was not supported by lower hemoglobin A1c levels 
as an indicator of diabetic control or daily insulin requirement.  
Another phase II trial studies the effects of DiaPep277 in 2 stages (Lazar et al., 2007). In the 
first stage, 17 patients received four injections of 1 mg DiaPep277 at months 0, 1, 6, and 12, 
and 18-month, and preservation of endogenous insulin secretion was observed up to 18 
months. In the second stage, which was only for those who completed stage 1 including 
placebo with C-peptide above 0.1 nmol/L, patients continued treatment with DiaPep277 ( 
six patients, 1 mg DiaPep277 at months 0, 3, 6, and 9), and those switched from placebo to 
DiaPep277 (thirteen patients, 1 mg DiaPep277 at months 0, 3, 6, and 9) manifested a trend 
towards a greater preservation of beta-cell function compared to five patients maintained on 
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and seven patients switched to placebo (Raz et al., 2007). Conversely, a trial with recent 
onset diabetic children (7-14 years old) showed no beneficial effect in preserving beta-cell 
function or improving metabolic control. 
Phase III trials of DiaPep277 are currently ongoing. The first Phase III study has begun in 
2005 in 40 centers worldwide (Fischer et al., 2010). The inclusion criteria include type 1 
diabetes for less than 3 months, ages 16 – 45, and C-peptide > 0.22 nmol/L. The treatment 
regimen includes nine injections of 1 mg DiaPep277 or placebo over 21 months and 3 
additional months of follow-up. At the end of recruitment in September 2009, 457 patients 
were randomly assigned to one of the groups and results are expected in September 2011. 
After an interim analysis, the Independent Data Monitoring Committee (IDMC) concluded 
that there were no safety concerns and that the study could be continued without 
modification. In addition, there is a clear treatment effect in different sub-group 
populations.  Two additional phase III trials are ongoing and will end in August and 
December of 2013. 
Immunological studies of the effects of DiaPep277 in human patients have revealed that the 
treatment is immunologically effective, specific and safe, when comparing T cell responses 
to specific antigen DiaPep277, related autoantigens heat shock protein 60, glutamic acid 
decarboxylase 65, and non-related third party antigen tetanus toxoid, between treatment 
and placebo (Huurman et al., 2008). Cytokine production in response to therapy was 
dominated by interleukin-10, and decreasing autoantigen specific T cell proliferation was 
associated with beta cell preservation. The investigators concluded that declining or 
temporary T cell proliferation in response to DiaPep277 may serve as an immunological 
biomarker for clinical efficacy. 
4.2 Insulin peptide vaccines 
Insulin is a hormone which is mainly responsible for regulating sugar and fat metabolism in 
the body. Insulin permits cells in the liver, muscle, and fat tissue to take up sugar from 
blood and store it as glycogen in the liver and muscle. Chronic high blood glucose, or 
hyperglycemia, can cause severe complications by damaging and impairing tissues via 
molecular mechanisms like protein glycosylation (Aronson, 2008). Since the onset of 
diabetes is the result of low levels of and ultimately no insulin secretion from pancreatic 
beta cells, injection of the insulin protein has been used as a replacement therapy to treat 
diabetes after its beneficial effects were discovered by Canadian scientists Frederick Grant 
Banting and Charles Best in 1921.  
The current standard means of delivering insulin as replacement therapy is subcutaneous 
injection because of its lower cost and ease of self-delivery compared to other methods. 
Other routes such as oral administration and intramuscular injection are not chosen because 
of loss of insulin function in the digestive tract and rapid dispersion of the hormone, 
respectively.  These limitations are not a concern when using insulin as a vaccine because 
only structural aspects of the molecule are needed, i.e., antigenicity instead of function.  
Various clinical trials have been conducted to test whether delivering insulin protein as a 
vaccine via different delivery routes can prevent or ameliorate type 1 diabetes. The Diabetes 
Prevention Trial network (DPT-1) screened 103,391 healthy individuals who were under 45 
years of age, islet antibody positive, and relatives of type 1 diabetic patients. Individuals at 
high risk of developing type 1 diabetes, i.e., at least 50% probability of developing type 1 
diabetes within 5 years, received insulin both short-term intravenously and long-term 
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subcutaneously (Schatz & Bingley 2001). In addition, individuals at moderate risk of 
developing type 1 diabetes, i.e., 25-50% probability of developing the disease within 5 years, 
received oral delivery of insulin. Results showed that subcutaneous injection of insulin did 
not slow type 1 diabetes onset, and that oral insulin did not delay or prevent the disease. 
Further studies of a subgroup with higher insulin autoantibody levels indicated that 
although oral insulin did not reduce insulin autoantibody levels, there was a possible delay 
in diabetic progression for approximately 4.5 years (Skyler et al., 2005, Barker et al., 2007). 
Accordingly, larger trials with more participants and similar standards of the oral insulin 
study are ongoing (Skyler 2008).  
In addition to insulin polypeptide, the B:(9-23) B chain peptide or its altered form contains a 
major epitope recognized by the immune system and could delay or prevent diabetes when 
administered subcutaneously and intranasally in non-obese diabetic mice (Daniel & 
Wegmann, 1996; Kobayashi et al., 2007). A phase I/II clinical trial of insulin B-chain in 
incomplete Freund's adjuvant (IBC-VS01), i.e., non-inflammatory, was conducted using a 
single intramuscular injection in a small group (12 patients) with recently diagnosed type 1 
diabetes (Orban et al., 2010). After two years, the patients developed robust insulin-specific 
humoral and T cell responses including insulin B-chain specific CD4 T regulatory cells, but 
did not show statistically different levels of C-peptide compared to the control group. 
Nevertheless, the results are meaningful because there is a growing body of evidence 
suggesting that autoimmunity observed in type 1 diabetes is the result of an imbalance 
between autoaggressive and regulatory cell subsets. Therefore, therapeutics that 
supplement or enhance the existing regulatory T cell subset could be beneficial. 
Over the years, multiple studies have shown that mucosal administrations of insulin orally 
and intranasally retard development of autoimmune diabetes in the non-obese diabetic mice 
(Bergerot et al., 1994; Harrison et al., 1996). Accordingly, a trial using intranasal delivery of 
insulin (Humulin) to 38 children (median age 10.8 years) at risk for type 1 diabetes was 
undertaken as part of the Melbourne Pre-Diabetes Family Study in Australia (Harrison et 
al., 2004). The results suggested that intranasal insulin induced immune changes consistent 
with mucosal tolerance to insulin, and did not accelerate loss of β-cell function. Conversely, 
additional trials with 224 infant and 40 sibling relatives with HLA-DQB1 susceptibility allele 
genotypes and two or more autoantibodies at three university hospitals in Finland did not 
prevent or delay type 1 diabetes (Näntö-Salonen et al., 2008).  
Altogether, results from these different clinical trials indicate that the pre-clinical success of 
insulin as an immunoregulatory vaccine in non-obese diabetic mice has not yet successfully 
translated in humans. Interestingly, evidence suggests that insulin may be the initiator 
autoantigen in type 1 diabetes, in other words, loss of tolerance to insulin could be the 
trigger of the disease (Harrison, 2008). Hypothetically, this loss of tolerance mechanisms for 
insulin could explain the difficulty in inducing tolerance in humans using therapeutic 
insulin vaccines. On the other hand, insulin may be a target of choice to prevent disease 
when mechanisms of tolerance to insulin are still in place in pre-diabetic individuals. 
4.3 Glutamic acid decarboxylase 65 protein vaccine 
In contrast with clinical trials using insulin polypeptide and peptide vaccines, the first human 
trials with glutamic acid decarboxylase 65 autoantigen as a therapeutic vaccine have shown 
beneficial therapeutic results (Ludvigsson & Linköping Diabetes Immune Intervention Study 
Group, 2009). Glutamic acid decarboxylase 65 is an enzyme that catalyzes the synthesis of 
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gamma-aminobutyric acid (GABA), which acts as a neuroinhibitor as well as an 
immunoregulatory molecule. Several observations suggest that glutamic acid decarboxylase 65 
may have a critical early role in mediating islet beta cell destruction. Detection of anti glutamic 
acid decarboxylase antibodies in the sera of prediabetic patients is a reliable predictive marker 
for the progression to overt diabetes, and anti glutamic acid decarboxylase reactivity can be 
detected in non-obese diabetic mice very early in the disease process (Ludvigsson & Linköping 
Diabetes Immune Intervention Study Group, 2009; Tisch et al., 1994).  
Evidence for a role for the protein in disease etiology came from experiments reporting that 
delivery of glutamic acid decarboxylase 65 either intravenously or intrathymically into female 
non-obese prediabetic mice can prevent insulitis and diabetes (Kaufman et al., 1993; Tisch et 
al., 1993). Additional reports showed that intravenous delivery of glutamic acid decarboxylase 
65 once every three days for a total of four injections of 200 micrograms from age 12-week can 
prevent diabetes from 70% in controls down to 20% in treated animals at week 35 through 
induction of glutamic acid decarboxylase 65 specific CD4 T regulatory cells (Tisch et al., 1998). 
Furthermore, injection of glutamic acid decarboxylase 65, but not heat shock protein pep277 or 
insulin B-chain, can increase survival of syngeneic islets transplanted into diabetic mice 
through modulation of T-helper 1/T-helper 2 balances (Tian et al, 1996).  
The first results of phase I/II clinical trials using subcutaneous delivery of 4, 20, 100, and 500 
micrograms of alum-formulated human recombinant glutamic acid decarboxylase 65 to 
eight patients with Latent Autoimmune Diabetes in Adults (LADA) were reported in 2005. 
Data showed that only the 20 microgram dose could increase both stimulated and fasting C-
peptide levels and T regulatory cells from baseline over the 24-week period. A 5-year follow 
up study found that the 20 microgram dose, and to a lesser extent the 4 and 100 microgram 
doses, could maintain C-peptide levels compared to the placebo group (Agardh et al., 2005; 
Agardh et al., 2009).  
In addition, seventy children and adolescents aged 10–18 years with recent onset type 1 
diabetes participated in a phase II trial (Ludvigsson et al., 2011). Participants received either 
a subcutaneous injection of 20 microgram of the alum formulated glutamic acid 
decarboxylase 65, or placebo at baseline and 1 month later. Although there was no statistical 
significant differences in fasting C-peptide levels between the glutamic acid decarboxylase 
65 and the placebo groups, those patients who were treated within 6 months of diabetes 
diagnosis had fasting C-peptide levels that decreased significantly less in the glutamic acid 
decarboxylase 65 group after 4 years compared with the placebo group. These results are 
significant because they indicate that, in contrast with Diapep277, glutamic acid 
decarboxylase vaccination is applicable to diabetic children who represent a large segment 
of the population with type 1 diabetes. However, in May 2011 it was reported that a 
European Phase III study with the antigen did not meet the primary efficacy endpoint of 
preserving beta cell function at 15 months, although a small positive effect was seen. 
With regard to immune responses induced by alum-formulated glutamic acid decarboxylase 
65 in human, a reduced percentage of IgG1 and increased IgG3/IgG4 antibodies were 
detected in treated children after 3 months, which suggested a T helper-2 deviation in the 
immune system. In addition, levels of IA-2A, IgE and tetanus toxoid antibodies as well as 
glutamic acid decarboxylase enzyme activity were unaffected, which suggested specificity 
of the treatment (Chéramy et al., 2010; Ortqvist et al., 2010). Importantly, injection of the 
glutamic acid decarboxylase 65 protein vaccine enhances the percentage of 
CD4+CD25highFOXP3+ T regulatory cells, and induces secretion of interleukin-5, interleukin-
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10, and interleukin-13 correlating with the expression of CD4+CD25highFOXP3+ cells 21 to 30 
months after treatment in 35 patients aged 10–18 years (Hjorth et al., 2011). 
Vaccination with polypeptides/peptides to prevent and treat type 1 diabetes appears to be 
well-tolerated and safe in humans; however, the possibility of adverse events cannot be 
completely ignored. For example, insulin allergy occurs in less than 1% of diabetic patients 
treated with insulin peptide (Zhang et al., 2008). In these patients, different methods have 
been used for the treatment of insulin allergy including use of different insulin or insulin 
formulations. Allergic reactions range in severity from erythema and pruritus to life-
threatening anaphylaxis.  Indeed, vaccines inducing T helper-2 like responses can induce 
lethal anaphylaxis in non-obese mice (Overbergh et al., 2003, Pedotti et al., 2003), and may 
be less preferable compared to vaccines inducing regulatory cells like Foxp3 and T 
regulatory-1 T lymphocytes. 
5. DNA vaccine based immunotherapies 
DNA vaccines generally consist of bacterial plasmid DNA engineered to synthesize an 
antigen and other gene products after injection into a recipient. Compared to 
polypeptide/peptide vaccine immunotherapies, DNA vaccines bear several unique 
advantages, such as rapid development and standardized production, lower cost of storage, 
and synthesis over time of the chosen antigen in its native conformation. 
The first DNA vaccines were designed to induce immunogenic responses to pathogens and 
cancer but have increasingly been applied to induce immune tolerance for autoimmune 
diseases like type 1 diabetes. DNA vaccines and other gene-based vaccines belong to a third 
generation of vaccines following live and attenuated whole organism vaccine and 
recombinant protein vaccines.  Recent reports of beneficial results in different clinical trials 
indicate that DNA vaccination is reaching a stage where we are likely to see accelerated 
development of a therapeutic future of DNA vaccines for a variety of diseases.  In the case of 
type 1 diabetes, early results using a DNA vaccine encoding insulin have shown promise in 
clinical trials, confirming the notion that DNA vaccines may be particularly well suited for 
promoting immune tolerance in humans compared to effects desired for infectious diseases 
and cancer. In addition, DNA vaccines encoding heat shock protein 60 or 65 and glutamic 
acid decarboxylase 65 have also shown efficacy in mice and are reviewed in this chapter.  
5.1 Heat shock protein 60 or 65 DNA vaccines 
As mentioned previously, Pep277 derived from mammalian heat shock protein 60 has 
shown protective effects in both pre-clinical and clinical trials. With regard to DNA 
vaccination, two 100 microgram intramuscular injections of plasmid DNA coding for 
mammalian heat shock protein 60 into 4-week old non-obese diabetic mice can prevent 
cyclophosphamide accelerated diabetes, i.e., 30% of treated mice develop diabetes compared 
with 60% diabetic in vector treated controls (Quintana et al., 2002).  Disease prevention is 
associated with reduced T cell proliferation, an increase in interleukin-10 and interleukin-5 
secretion, and a decrease in interferon-gamma secretion, which suggests a shift from a T 
helper-1 like toward a T helper-2 like immune response. 
Furthermore, plasmid DNA encoding mycobacterial 65-kDalton heat shock protein caused 
decreased insulitis when injected intramuscularly in three doses (100 micrograms each) 
administered at 2-week intervals into 6- to 8-week-old, streptozotocin-induced diabetic 
C57BL/6 mice (Santos et al., 2009). The treatment was associated with the appearance of a 
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regulatory cell population in the spleen, with higher production of interleukin-10 in spleen 
and islets, and with a decreased infiltration of CD8 T lymphocytes in the islets. The same 
DNA vaccine with the same dose and delivery reduced the occurrence of diabetes from 
100% to 33% in 28-week old non-obese diabetic mice when injected at 4-week of age, and 
was associated with a reduction in CD4 and CD8 T cells infiltration, appearance of CD25 
cells, and increased levels of interleukin-10 in the islets (Santos et al., 2007). 
5.2 Insulin DNA vaccines 
Insulin-encoding plasmid DNA is the only type of DNA vaccine that has been tested in both 
preclinical and clinical trials for type 1 diabetes. The initial report demonstrating feasibility of 
this concept used a virus-induced diabetic mouse model system to show that intramuscular 
inoculation of plasmid DNA encoding the insulin B chain reduces the incidence of diabetes 
(blood glucose > 350 mg/dl) from 100 to 50% (Coon et al., 1999). DNA vaccination induced 
CD4 T regulatory cells that reacted with the insulin B chain, secreted interleukin-4, and locally 
reduced autoreactive activity of cytotoxic T lymphocytes in the pancreatic draining lymph 
nodes. The DNA vaccine also protected non-obese diabetic mice reducing diabetes onset from 
80% down to 25% depending on the presence of interleukin-4 (Bot et al, 2001).   
Rodent animals synthesize two isoforms of insulin, I in islets and II in both islets and 
thymus that are the products of non-allelic genes while humans have only one form of 
insulin. The pancreatic beta cells synthesize proinsulin before converting it to functional 
insulin (Sizonenko & Halban, 1991). Intranasal delivery of plasmid DNA encoding mouse 
proinsulin II (3 50 micrograms doses over a 2-week interval starting at 4 weeks of age) 
together with an anti-CD154 antibody (3 doses of 300 microgram over 2-week interval 
from 4 weeks of age) prevented type 1 diabetes by reducing the incidence in 40-week old 
mice from 100% diabetic animals down to 0%. On the other hand, intranasal delivery of 
the DNA vaccine alone did not prevent disease, but did induce regulatory T cells (Every 
et al., 2006). In contrast to prototypic CD4+ CD25+ T regulatory cells, the CD4 T regulatory 
cells induced by the proinsulin DNA vaccine alone were both CD25+ and CD25-, and were 
not defined by markers such as glucocorticoid-induced TNFR-related protein (GITR), 
CD103, or Foxp3. 
Another report showed that co-delivery of a DNA vaccine encoding human proinsulin (50 
microgram) and insulin peptide (100 microgram) intramuscularly twice over 2-week 
intervals starting when the mice were 6 weeks of age prevents diabetes in non-obese 
diabetic mice until 24 weeks of age, but not the DNA or peptide vaccine alone (Zhang et al., 
2010). Results also indicated that the induction of transforming growth factor-beta 
producing CD4+CD25- islet specific T regulatory cells was observed only in the co-
immunization group, but not in the DNA or the protein vaccine alone group, which 
confirmed a synergistic effect.  
Among the most promising reports of insulin DNA vaccination is a plasmid DNA vaccine 
encoding mouse proinsulin II, which reduces the incidence of diabetes in non-obese 
diabetic mice when administered intramuscularly to prediabetic 8-week old mice, and to 
diabetic mice older than 12-week old with blood glucose > 170 mg/dL (Solvason et al., 
2008). The efficacy of the vaccine was improved by increasing the level of expression of 
insulin, frequency of dosing, dosage, and subcellular localization modification of the 
autoantigen to the intracellular compartment instead of secretion. In the prophylactic 
setting, the DNA vaccine decreased the incidence of diabetes from 80% in the control 
group down to 45% in 25-week old mice receiving weekly administration of 50 
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micrograms of the vaccine. The treatment caused increased numbers of interferon-gamma-
secreting cells and a decrease in insulin autoantibodies.  In the therapeutic setting, the 
DNA vaccine reduced progression to overt diabetes from 100% in the control groups 
down to 25% in treated mice (observation made at 25 weeks post treatment initiation). 
Treatment consisted of weekly delivery of 50 microgram of the vaccine for a total of 9 
injections. The treatment induced increased numbers of insulin-specific interferon-
gamma-producing T cells and levels of interleukin-10, which suggested induction of T 
regulatory-1 cells. Adoptive transfer experiments indicated that the protection was not 
mediated by induction of CD4+CD25+ T regulatory cells.  
Importantly, a similar vaccine was used in the only human trial of a DNA vaccine for 
diabetes conducted to date (Gottlieb et al., 2008). The plasmid DNA vaccine (BHT-3021) has 
undergone a Phase I/II trial using four doses of plasmid DNA, i.e., 0.3, 1, 3 and 6 
milligrams, administered intramuscularly once a week for 12 weeks.  The interim results for 
the 1 mg dose showed pancreatic beta-cell preservation, demonstrated by a mean 17% 
increase in C-peptide levels with BHT-3021 by week 15 after enrollment, whereas placebo 
patients experienced a mean 42% decrease in C-peptide. Evidence for immune tolerance was 
suggested by a mean 17% reduction in anti-insulin antibodies, and 25% reduction in anti-
glutamic acid decarboxylase 65 antibodies by week 15 after enrollment, whereas placebo 
patients experienced a mean 6% and 4% increase, respectively. The most recent report of the 
trial claimed that BHT-3021 preserves C-peptide levels for at least six months and one year 
in some of the patients from the point of initiation of the therapy (Garren, 2009). These 
results together with its favorable side-effects profile appear to be comparable to those 
reported with anti-CD3 monoclonal antibody and the glutamic acid decarboxylase 65 
protein vaccines for type 1 diabetes. 
5.3 Glutamic acid decarboxylase DNA vaccines 
DNA vaccines encoding glutamic acid decarboxylase 65 are currently at the preclinical 
stage. The first report of a beneficial effect in non-obese diabetic mice showed that plasmid 
DNA encoding wild-type intracellular or engineered secreted glutamic acid decarboxylase, 
i.e., a fusion of the interleukin-2 signal peptide with a truncated form of human glutamic 
acid decarboxylase 65, causes decreased insulitis compared to plasmid vector alone when 
delivered intramuscularly, and is accompanied by higher secretion of interleukin-4 by 
splenocytes (Liu et al., 1999). A subsequent report indicated that only the DNA vaccine 
encoding secreted glutamic acid decarboxylase could suppress cyclophosphamide-
accelerated diabetes in 4-week old female non-obese diabetic mice with a tendency to 
increase T helper-2 like activity when 2 x 400 micrograms were delivered intramuscularly 
over 2 days (Filippova et al., 2001). 
Another report published the same year corroborated the notion that secretion of glutamic 
acid decarboxylase encoded by a DNA vaccine is important to ameliorate diabetes in mice 
(Weaver et al., 2001). In this report, plasmid DNA was engineered to encode a secreted 
fusion protein of a truncated form of glutamic acid decarboxylase 65 and an IgG Fc fragment 
as well as interleukin-4. Intramuscular injection of 50 micrograms of the vaccine effectively 
prevented diabetes in non-obese diabetic mice treated at early (4-week old, 3 times weekly) 
or late (12-week old, 4 times weekly) preclinical stages of diabetes. Diabetic onset reduction 
went from 75% in controls down to 25% at week 50+ and from 70% to 20% at week 55+. 
Protection was dependent on the vaccine-encoded interleukin-4 and endogenous 
interleukin-4, and was associated with induction of glutamic acid decarboxylase 65 specific 
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regulatory T helper-2 cells (Tisch et al., 2001). However, when the same vaccination strategy 
was applied using insulin, the vaccine encoding insulin B chain/IgG Fc fusion protein and 
interleukin-4 caused accelerated progression of insulitis and diabetes, which was correlated 
with an increased number of interferon-gamma secreting T cells in response to insulin B 
chain specific peptides (Weaver et al., 2001).  
In addition, a study reported that a DNA vaccine encoding full-length intracellular human 
glutamic acid decarboxylase 65 could prevent spontaneous diabetes when delivered at week 
4 or week 10 of age using intramuscular injection of 2 x 50 micrograms in non-obese diabetic 
mice (Balasa et al., 2001). Notably, disease prevention was associated with CD28/B7 
costimulation because co-expression of B7-1 or B7-2 and glutamic acid decarboxylase 65 by 
the same DNA vaccine abrogated protection.  
With regard to DNA vaccination and the effects of interleukin-4, a virus-induced murine 
diabetes model was used to study the relationship between different endogenous expression 
levels of islet autoantigen in beta-cells and the efficacy of DNA vaccination (Wolfe et al., 
2002). Lower expression levels of a model autoantigen in beta-cells support immune 
regulation resulting in induction of autosuppressive regulatory cells characterized by 
increased interleukin-4 production (T helper-2 like). In contrast, higher levels of the 
autoantigen favor T helper-1 like autoaggressive responses characterized by increase 
interferon-gamma generation. Immunization with a DNA vaccine coding the autoantigen 
and interleukin-4 reduced the risk of augmenting autoaggression and thus increased the 
safety margin of this immune-based therapy. 
DNA vaccines encoding secreted glutamic acid decarboxylase and anti-inflammatory 
interleukins have also been applied to transplantation for type 1 diabetes. Survival of 
syngeneic neonatal pancreata transplanted under the kidney capsule of non-obese diabetic 
mice is promoted by intramuscular injection of a DNA vaccine encoding the secreted 
glutamic acid decarboxylase 65/IgG Fc fusion and interleukin-4 plus interleukin-10 (Seifarth 
et al., 2003). The treatment consisted of 50 micrograms of the vaccine delivered weekly for 
four weeks from the age of 10 weeks with transplantation performed one week after the 
final DNA vaccination. The DNA vaccination protected the syngeneic islet transplanted 
mice from 100% diabetic mice in controls down to 20% diabetes incidence in treated animals 
at 30 weeks of age, 15 weeks post transplant, but required co-delivery of both interleukin-4 
and interleukin-10. Increased islet survival correlated with a marked reduction in interferon-
gamma reactivity that is glutamic acid decarboxylase 65 specific, and an increase in 
interleukin-10-secreting T cells. These results made apparent the increased difficulty in 
protecting exogenous syngeneic islet compared with endogenous islets, and the need for 
more stringent conditions of vaccination in the transplantation setting. 
Intramuscular injection has traditionally been used for DNA vaccination because it permits 
delivery of larger amounts of DNA, and is commonly used in the clinic. Nonetheless, other 
routes of delivery may be more advantageous to induce tolerogenic responses. A report 
compared intramuscular, intradermal, and oral delivery of plasmid DNA coding for the 
intracellular or secreted form of glutamic acid decarboxylase for prevention of diabetes in a 
4-week-old non-obese diabetic mouse model system (Li & Escher, 2003). Results showed 
that both intradermal and oral deliveries were more effective than intramuscular delivery 
for delaying the disease, and cytokine-specific ELISpot analysis indicated that immune 
responses induced by the DNA vaccines were more dependent on the cellular localization of 
glutamic acid decarboxylase antigen than on the delivery route. In contrast, ELISA indicated 
that intradermal delivery of DNA was most likely to induce a T helper-2 like response. 
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In addition to route of delivery, the method used to administer a DNA vaccine can be 
beneficial by directly improving immune responses and permitting lower vaccine dosage. 
For example, dermal delivery of plasmid DNA using gene gun technology, which consists 
in shooting microscopic metal particles covered with the vaccine, can improve protection 
from diabetes. In this regard, gene-gun delivery of 1 microgram of a DNA vaccine encoding 
the secreted glutamic acid decarboxylase 65/IgG Fc fusion polypeptide into 10-week old 
non-obese diabetic mice was compared with intramuscular injection of 50 micrograms of the 
same vaccine (Goudy et al., 2008). Results showed that in both cases gene expression peaked 
at week 8 post deliveries, and was maintained until at least week 35 with more than 40% 
higher expression from the gene-gun delivery. However, only gene-gun delivery could 
protect from diabetes with 90% diabetic in controls down to 50% diabetic at 35 weeks of age 
that was associated with induction of interleukin-4 secreting CD4 T cells. In contrast, 
intradermal gene-gun administration of plasmid-DNA encoding intracellular glutamic acid 
decarboxylase 65 to 3-week old non-obese diabetic mice does not suppress diabetes in non-
obese diabetic mice (Joussemet et al., 2005). The different results might be attributed to the 
different subcellular localizations of the autoantigen. 
So far in this section we have described how DNA vaccines can be engineered to enhance 
tolerogenic-like immune responses by co-delivering cytokine-encoding DNA, engineering 
subcellular localization of a target autoantigen, and choosing an effective route and method 
of delivery. The results obtained by different laboratories illustrate the promising potential 
of DNA vaccination as a safe, low-cost and patient-friendly means to treat autoimmune 
diabetes and other immune-mediated inflammatory disorders. Yet, as with all 
immunotherapies that seek safe means of improving the life of diabetic individuals, there is 
a pressing need to improve treatment efficacy. We strongly believe that one of the solutions 
to this problem is to mimic how the immune system maintains immune tolerance in 
peripheral tissues. DNA vaccination is particularly well-suited to achieve this goal because 
of the ability of plasmid DNA to deliver genetic instructions directly in situ for a limited 
time span and with low levels of danger signals known to activate proinflammatory 
immune responses.  Here, we briefly discuss vaccine-induced apoptosis as a possible means 
to mimic physiological immune tolerance and to approach the “Holy Grail” of 
immunotherapy, namely, the ability to suppress inflammation in a homeostatic manner 
(Figure 3).  
Apoptosis is a constantly on-going form of cell death that produces fifty to seventy billion 
dead cells on a daily basis in the average human adult (Reed, 1999).  Upon a given intrinsic 
or extrinsic signal, cells initiate the process of apoptosis and become membrane-bound 
cellular fragments, or apoptotic bodies, which are rapidly engulfed and processed by 
surrounding living cells. For many years it was believed that these apoptotic bodies had 
little effect on the immune system. Today, it is becoming increasingly clear that apoptotic 
cells play a fundamental role in both establishing and maintaining peripheral immune 
tolerance as they not only serve as a source of self-antigens to maintain immune tolerance, 
but also recruit antigen-presenting cells, secrete anti-inflammatory cytokines, and display 
tolerogenic molecules (Birge and Ucker, 2008).  The remarkable capacity of apoptotic cells to 
induce either tolerogenic immune responses or immunogenic responses depending on 
signals received makes them attractive candidates to intervene in many disorders like 
infectious diseases, cancer, and autoimmune diseases. 
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Fig. 3. Possible events following intradermal injection of a pro-apoptotic DNA vaccine 
coding for secreted pancreatic autoantigen glutamic acid decarboxylase (GAD). The 
plasmid DNA vaccine can transfect a variety of cell types at the chosen site of vaccine 
delivery, e.g., fibroblasts and keratinocytes in the case of intradermal injection.  Dendritic 
cells (DC) recruited by vaccine-induced apoptotic cells can uptake and process GAD-
containing apoptotic cells induced by the vaccine as well as vaccine-encoded secreted GAD, 
and present GAD on major histocompatibility complex class I and II molecules. The 
dendritic cells then migrate to lymph nodes and spleen where they can induce tolerogenic 
immune responses. 
An important feature of pro-apoptotic DNA vaccination is that it permits the manipulation 
of physiological apoptosis both de novo and in situ. This is important because apoptotic cells 
synthesize a variety of immune molecules with levels that are most likely physiologically 
relevant in the context of a microenvironment. The concept of immunological 
microenvironment is also crucial to immune responses induced by dendritic cells, which are 
equipped to sense and act upon changes in their immediate vicinity. Therefore, induction of 
apoptosis by DNA vaccination could be a way to have access to homeostasis and maintain 
non-responsiveness to self. 
The first report of DNA vaccines designed for pro-apoptotic immunoregulation, i.e., anti-
inflammatory, used plasmid DNA coding for the pro-apoptotic BAX protein and intracellular 
or secreted glutamic acid decarboxylase, to prevent diabetes in the non-obese diabetic mouse 
(Li et al., 2004). Results indicated that intramuscular injection of the BAX cDNA recruited 
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dendritic cells carrying vaccine-encoded protein in both spleen and lymph nodes. 
Furthermore, delivery of 2 x 150 micrograms plasmid DNA coding for secreted glutamic acid 
decarboxylase and BAX at a 3 days interval into 4-week old mice could prevent diabetes, i.e, 
reduce the incidence from 93% in controls down to 47% in treated animals. In contrast, the 
vaccines coding for BAX or secreted glutamic acid decarboxylase DNA alone or intracellular 
glutamic acid decarboxylase and BAX did not prevent diabetes. Notably, ELISA results 
indicated that co-delivery of BAX suppressed T helper-2 like activity which indicated that 
another cell type was responsible for disease suppression. Indeed, a subsequent report showed 
that delivery of both secreted glutamic acid decarboxylase and BAX were required to induce 
CD4+CD25+FoxP3+ cells with contact dependent regulatory activity that was independent of 
transforming growth factor-beta and interleukin-10 (Li et al., 2006). 
Importantly, additional studies revealed that increased CpG methylation of the DNA 
vaccine together with delivery of secreted glutamic acid decarboxylase and BAX DNA acted 
synergistically to ameliorate recent onset of diabetes in non-obese diabetic mice (Li et al., 
2010). Mice receiving a weekly intradermal injection of 50 micrograms of the vaccine over 
eight weeks following early diabetes ameliorated diabetes from 90% diabetic in controls 
down to 20% in treated mice at 40 weeks of age. It is hypothesized that increased CpG 
methylation of plasmid DNA makes the DNA vaccine appear more mammalian-like to the 
immune system, as it is known that bacterial DNA has low levels of CpG methylation that 
can act as an inflammatory signal (Krieg, 2002). Taken together these results indicate that 
apoptosis-inducing DNA vaccination is a promising approach for treatment of type 1 
diabetes. 
5.4 Comparing DNA vaccines and polypeptide/peptide vaccines 
Compared to polypeptide/peptide vaccine, the main advantages of DNA vaccines are: 1) 
known process of manufacturing, i.e., plasmid DNA can be isolated using a standard 
procedure while different polypeptides may require different protocols that have to be 
optimized for a specific antigen; 2) Cost-effective shipment and storage because plasmid 
DNA does not require refrigeration; 3) A more sustained expression of the antigen in its 
native conformation, or shape, instead of a purified antigen that can adopt different non-
native conformations; and 4) Expression of the whole protein rather than specific epitopes in 
the case of peptides to ensure delivery of full antigenic signals that can be recognized by 
different major histocompatibility complex molecules in an outbred human population. 
6. Other immunotherapies 
There are currently other ongoing immunotherapies, such as the applications of Bacille 
Calmette-Guérin (BCG), Vitamin D3, nicotinamide, immunosuppressants, nanoparticles, 
and antisense oligonucleotides, etc., which have certain effects in suppressing type 1 
diabetes in non-obese diabetic mice. Bacille Calmette-Guérin is a vaccine that is prepared 
from a strain of attenuated live bovine tuberculosis bacillus that has lost its virulence in 
human, which has been used as a vaccine to prevent tuberculosis. Although it has shown 
efficacy in animal models, clinical trials in recent onset diabetic children have been 
disappointing (Elliott et al., 1998; Allen et al., 1999).  
Several clinical trials of vitamin D3 have been conducted since the 1990s, and results showed 
either temporary effects (Pitocco et al., 2006; Li et al., 2009), or no effects (Walter et al., 2010; 
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Bizzarri et al., 2010) on protecting pancreatic beta-cell function in child or adult type 1 
diabetic patients. 
Nicotinamide is a molecule belonging to the vitamin B group, i.e., vitamin B3, and has anti-
inflammatory effects in vivo. The first report of clinical trials on type 1 diabetes was 
published in the mid 1980s (Vague et al., 1987), followed by multiple trials conducted 
worldwide with complex results. When using 25 mg/kg or 1.2 g/m2 body surface/day of 
the vitamin B, most of the recent reports showed that nicotinamide has no protective effect 
on type 1 diabetes in new-onset patients or high-risk relatives (Pitocco et al., 2006; Skyler, 
2008), even though it induces decreased spontaneous and in vitro autoantigen-induced 
interferon-gamma secretion in high-risk relatives who develop type 1 diabetes and may play 
a role in immune regulation (Hedman et al., 2006). Only one of the reports showed that 
nicotinamide treatment results in higher C-peptide values at 3 months and lower insulin 
requirement at 1 year in pancreatic interleukin-2 accumulated diabetic patients post 1 year 
treatment (Chianelli et al., 2008). 
The immunosuppressant cyclosporin A was employed in the first trials showing effects of 
immune therapies on T1D. Continuous cyclosporin A treatment initiated soon after 
diagnosis eliminated the need for exogenous insulin (Bougneres et al., 1988; Stiller et al., 
1984). Nevertheless, the lack of lasting effects and renal toxicity of the drug diminished 
enthusiasm for this approach and other broad-spectrum immune modulating agents such as 
azathioprine and prednisone (Bougneres et al., 1990; Silverstein et al., 1988). 
The Major Histocompatibility Complex (MHC) genomic region is found in most vertebrates 
and encodes protein molecules playing an important role in immunity and recognition of 
antigens by T cells. It has been shown that nanoparticles loaded with diabetes relevant 
peptide-major histocompatibility complexes prevent and treat diabetes when administered 
intravenously in non-obese diabetic mice (Tsai et al., 2010). The treatment prevented 
diabetes from 75% in control down to 25% in 30-week-old non-obese diabetic mice (4-week 
old mice received 7.5 mg every 2 weeks until the 3rd injection and every 3 weeks thereafter), 
and restored normoglycemia in diabetic mice (blood glucose higher than 11 mM mice 
received 7.5 mg twice a week for 5 week). The treatment expanded CD8+ regulatory T cells 
which suppressed local presentation of autoantigens in an interferon-gamma, indoleamine 
2,3-dioxygenase, and perforin dependent manner. Furthermore, adoptive transfer of CD8+ 
but not CD4+ splenocytes suppressed diabetes and restored normoglycemia in a humanized 
diabetic mouse model. 
Antisense oligonucleotides are single strands of DNA or RNA that are complementary to 
chosen sequences of target messenger RNAs. Antisense DNA oligonucleotides for 
messenger RNAs coding for CD40, CD80, and CD86 were delivered subcutaneously into 5- 
to 8-week old non-obese diabetic mice using 50 micrograms of a 1:1:1 mixture of each 
antisense oligonucleotides administered weekly for eight consecutive weeks (Phillips et al., 
2008). The treatment prevented disease in 25 % of mice compared to 100 % diabetes in 
control animals.  A similar treatment was given to diabetic mice with blood glucose higher 
than 300 mg/dL three times a week maintained blood glucose lower than 200 mg/dl for 50+ 
days compared to higher than 200 mg/dL in control mice. The treatment decreased CD40, 
CD80, and CD86 cell surface expressions on dendritic cells in spleen, and augmented Foxp3+ 
T regulatory cells numbers with hyporesponsiveness to self-antigen but not to alloantigen. 
In addition, spleen T-cells adoptive transfer from treated mice could suppress diabetes, 
confirming the induction of regulatory T cell activity. 
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7. Combinatorial approaches - the future of immunotherapy? 
Combination immunotherapies are increasingly being considered, since none of the 
immunotherapies alone have reported thus far long term remission of type 1 diabetes (Li et 
al., 2008; Luo et al., 2010; Bluestone et al., 2010). This is especially true in view of the 
announcements in 2011 of failure of the anti-CD3 and glutamic acid decarboxylase protein 
vaccine therapeutic phase III trials for type 1 diabetic patients. Type 1 diabetes is an 
autoimmune disease correlated with multiple autoantigens and autoantibodies, and 
possible dysfunction in several cell types and associated cytokines. Therefore it is reasonable 
to anticipate a variety of synergistic effects that may be induced by combination therapies, 
as demonstrated in animal model systems. For example, a novel combination treatment with 
anti-CD3 epsilon specific antibody and intranasal delivery of proinsulin peptide can reverse 
recent onset diabetes in non-obese diabetic mice and a virus-induced diabetic mouse model 
with much higher efficacy than with monotherapy using anti-CD3 or the peptide alone 
(Bresson et al., 2006). Protection is associated with expansion of CD25+ Foxp3+ and insulin 
specific T regulatory cells producing cytokines, such as interleukin-10, transforming growth 
factor-beta, and interleukin-4. In addition, these cells can transfer dominant tolerance to 
immunocompetent recent onset diabetic recipients, and suppress heterologous 
autoaggressive CD8 T cell responses.  
As mentioned previously, another synergistic effect was reported with prime boosting using 
DNA vaccine encoding proinsulin plus insulin protein vaccine to prevent new onset diabetes 
in non-obese diabetic mice. The induction of the transforming growth factor-beta producing 
CD4+CD25– islet specific T regulatory cells against the onset of diabetes was observed only in 
the combination therapeutic group, but not in the monotherapy groups (Zhang et al., 2010).  
Standard clinical complex therapeutic protocol for controlling allo organ transplant rejection 
may be used as an example of combinatorial therapy where various drugs can be used in 
combination or alone at different times to increase allograft survival. Single therapy alone 
has its limits, ranging from targeting a single arm of the immune process, lower efficacy, 
and higher possible adverse effect due to higher dose requirement. Combination therapies 
could be used to overcome these problems. The combinations could include antibody or 
cytokine therapy combined with polypeptide/peptide and DNA vaccine, DNA vaccination 
combined with polypeptide/peptide vaccine and cellular therapy, as well as other 
combinations (Figure 4).  
Considering the number of approaches that have been developed for the treatment of type 1 
diabetes over the years, there is a significant number of possible combinations of different 
therapies. Yet we cannot exclude the possibility that platform technologies that provide 
access to a wide array of possible gene-based therapeutic enhancements could still perform 
satisfactorily on their own at lower cost. Our work with pro-apoptotic DNA vaccination 
does indicate that combining different properties of DNA vaccines alone can result in potent 
synergistic effects (Li et al., 2010). In addition, different combinations of autoantigens and 
vaccine technologies could still yield significant therapeutic improvements in the clinic. For 
example, the fact that GAD65 polypeptide appears to be a better therapeutic vaccine than 
insulin polypeptide/peptide vaccines combined with the promising results of the DNA 
vaccine encoding pro-insulin suggests the possibility that GAD65 might be a better 
autoantigen than insulin for therapy of T1D, and that plasmid DNA could improve efficacy 
of vaccination compared to an equivalent protein vaccine. Therefore, a DNA vaccine coding 
for GAD65 could be particularly beneficial for treatment of T1D. 
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Fig. 4. Hypothetic Models of Combinatorial Immunotherapies for Type 1 Diabetes. 
Because of their increased safety compared to other approaches, antigen-based vaccines are 
the most likely to be applied to type 1 diabetes prevention. Combinatorial approaches for 
disease prevention could use prime-boosting with DNA and polypeptide vaccines. A body 
of evidence has shown the beneficial effects of this type of approach for infectious diseases 
and cancer, and initial results suggest that it is also applicable to type 1 diabetes. Antibodies 
like anti-CD3 may not be readily applicable to diabetes prevention for reasons of safety and 
efficacy, but could be used as induction therapy followed by prime-boost with 
DNA/polypeptide vaccines. 
Clearly, the immunotherapeutic tools that have been generated over the past decade offer 
renewed hope for type 1 diabetic patients, as well as for the increasing number of 
individuals suffering from other chronic inflammatory disorders. We expect that in the near 
future, the development of novel therapeutic and preventive approaches, novel methods of 
delivery, and a better understanding of immunological mechanisms translated from animal 
models to human clinical studies and practices, will render the possibility of 
immunotherapy for type 1 diabetes a clinical reality. 
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